Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of aluminium hydroxide-adsorbed birch pollen allergoid immunotherapy
2005-000025-35Phase 3Completed
- Sponsor
- Allergopharma
- Start
- Mar 2005
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and allergic asthma comparing Active birch pollen allergoid immunotherapy with Placebo (2 arms). Primary endpoint: Area under the curve of Symptom-and-Medication Score after 2 years of double-blind treatment. Started Mar 2005; status: completed.
02
Drugs
Allergovit Birch
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2005-000025-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000025-35.